Suntrust Banks Inc. lifted its stake in Amedisys Inc (NASDAQ:AMED) by 4.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,702 shares of the health services provider’s stock after buying an additional 237 shares during the period. Suntrust Banks Inc.’s holdings in Amedisys were worth $358,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Riverhead Capital Management LLC raised its holdings in shares of Amedisys by 75.5% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after buying an additional 831 shares in the last quarter. Federated Investors Inc. PA raised its holdings in shares of Amedisys by 2.3% in the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after buying an additional 44 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of Amedisys in the 1st quarter worth approximately $123,000. CIBC Asset Management Inc acquired a new position in shares of Amedisys in the 2nd quarter worth approximately $230,000. Finally, SG Americas Securities LLC raised its holdings in shares of Amedisys by 48.7% in the 2nd quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock worth $235,000 after buying an additional 1,226 shares in the last quarter. 96.55% of the stock is owned by institutional investors and hedge funds.

In related news, insider David B. Pearce sold 1,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the sale, the insider now owns 10,488 shares of the company’s stock, valued at $524,400. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Bruce D. Perkins acquired 2,000 shares of Amedisys stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average cost of $46.60 per share, for a total transaction of $93,200.00. Following the purchase, the director now owns 15,825 shares of the company’s stock, valued at $737,445. The disclosure for this purchase can be found here. Insiders own 2.00% of the company’s stock.

A number of equities analysts have recently issued reports on the company. Mizuho cut Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a report on Wednesday, July 26th. Robert W. Baird reaffirmed a “hold” rating and set a $50.00 price target on shares of Amedisys in a report on Wednesday, October 4th. Bank of America Corporation began coverage on Amedisys in a report on Monday, August 21st. They set a “neutral” rating and a $55.00 price target for the company. BidaskClub raised Amedisys from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $60.00 price target on shares of Amedisys in a report on Thursday. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $56.20.

ILLEGAL ACTIVITY WARNING: “Suntrust Banks Inc. Buys 237 Shares of Amedisys Inc (AMED)” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/suntrust-banks-inc-buys-237-shares-of-amedisys-inc-amed/1629941.html.

Amedisys Inc (NASDAQ:AMED) opened at 47.80 on Friday. The firm has a 50-day moving average price of $51.83 and a 200-day moving average price of $55.12. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 40.85 and a beta of 0.87. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.12. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The company had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. During the same period in the prior year, the business earned $0.42 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities analysts anticipate that Amedisys Inc will post $2.21 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.